Clovis Oncology, Inc. CLVS Income Statement

Clovis oncology, inc. (CLVS)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Revenues:
Product revenue
42,564	39,307	37,603	32,978	33,118	30,351	22,757	23,757	18,523	17,040	16,806	14,620	7,045	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product revenue, net
-	-	-	-	-	-	-	-	-	-	-	-	-	78	0	0	0	0	0	0	0	-	-	-	-	-	0	0	-	0	0	0	0	0	0	0	0
License and milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	13,625	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses:
Research and development
68,221	72,473	77,896	70,746	62,031	71,210	63,887	52,707	43,543	38,019	38,924	33,108	32,447	54,454	54,338	67,729	74,608	75,995	76,138	60,368	56,750	50,149	34,965	28,440	24,151	22,544	16,063	15,816	12,122	18,284	15,458	12,590	12,562	12,440	11,566	9,679	7,041
Selling, general and administrative
42,598	45,168	41,811	48,029	47,761	49,148	42,495	44,864	39,274	38,523	35,011	36,149	29,224	12,190	9,162	9,552	9,827	8,238	8,331	7,204	6,751	5,605	5,267	5,265	5,320	5,545	4,312	3,492	3,218	2,771	2,762	2,680	2,425	2,036	1,714	1,705	1,405
Acquired in-process research and development
-	0	9,440	0	-	0	0	0	0	-	-	-	-	500	500	300	0	0	12,000	0	0	0	0	400	8,406	0	0	0	250	0	0	250	4,000	-	-	7,000	-
Other operating expenses
3,449	4,172	5,539	0	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of intangible asset
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	104,517	0	89,557	0	0	0	-	-	-	3,409	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent purchase consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	25,452	-516	26,882	-783	-764	-724	1,864	-888	-861	-822	405	-	-	-	-	-	-	-	-	-	-	-
Total expenses
124,576	130,966	144,032	126,437	118,317	127,318	111,919	102,770	87,195	80,244	77,333	72,359	63,206	67,214	64,000	156,646	84,951	146,908	97,252	68,336	64,225	53,890	41,120	34,966	42,108	28,494	20,375	19,308	15,590	-	-	-	-	-	-	-	-
Operating loss
-82,012	-91,659	-106,429	-93,459	-85,199	-96,967	-89,162	-79,013	-68,672	-63,204	-60,527	-57,739	-56,161	-67,136	-64,000	-156,646	-84,951	-146,908	-97,252	-68,336	-64,225	-53,890	-41,120	-34,966	-28,483	-28,494	-20,375	-19,308	-15,590	-21,055	-18,220	-15,520	-18,987	-14,476	-13,280	-18,384	-8,446
Other income (expense):
Interest expense
9,561	6,720	5,278	3,817	3,590	3,591	3,376	3,581	2,635	2,631	2,618	2,598	2,581	2,173	2,108	2,106	2,104	2,101	2,099	2,097	2,075	2,093	511	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency loss
-877	100	-229	-226	-192	-312	151	-104	-81	45	-44	76	-159	-146	-66	183	-551	736	-101	-1,142	3,247	1,001	2,323	316	-60	-606	-	-	-42	-	-	-	-	-	-	-	-
Loss on convertible senior notes conversion
-7,791	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal settlement loss
-	0	-1,750	-25,000	-	0	0	-20,000	-7,975	11,523	0	-117,000	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on extinguishment of debt
-	0	18,480	0	-	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
841	1,262	781	1,899	2,400	2,497	2,536	1,475	1,409	1,404	1,291	594	354	160	252	196	25	164	179	62	11	-106	-42	-46	-46	51	55	-33	36	-4	-48	-172	-4	-405	-555	-115	118
Other income (expense), net
-17,388	-5,358	12,004	-27,144	-1,382	-1,406	-689	-22,210	-9,282	10,341	-1,371	-118,928	-2,386	-2,159	-1,922	-1,727	-2,630	-1,201	-2,021	-3,177	1,183	-1,198	1,770	270	-106	-657	-	-	-78	-	-	-	-	-	-	-	-
Loss before income taxes
-99,400	-97,017	-94,425	-120,603	-86,581	-98,373	-89,851	-101,223	-77,954	-52,863	-61,898	-176,667	-58,547	-69,295	-65,922	-158,373	-87,581	-148,109	-99,273	-71,513	-63,042	-55,088	-39,350	-34,696	-28,589	-29,151	-20,320	-19,341	-15,668	-21,059	-18,268	-15,692	-18,991	-14,881	-13,835	-18,499	-8,328
Income tax benefit
-68	2,484	-350	-176	-160	888	13	-33	-260	-980	-1,234	-1,281	-83	1,433	-227	-29,059	-4,181	-28,568	-628	18	102	-181	292	68	2,129	52	-	-	-	0	0	-35	8	27	-	-	-
Net loss
-99,332	-99,501	-94,075	-120,427	-86,421	-99,261	-89,864	-101,190	-77,694	-51,883	-60,664	-175,386	-58,464	-70,728	-65,695	-129,314	-83,400	-119,541	-98,645	-71,531	-63,144	-54,907	-39,642	-34,764	-30,718	-29,203	-20,320	-19,341	-15,668	-21,059	-18,268	-15,657	-18,999	-14,908	-13,835	-18,499	-8,328
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax
-103	-123	-143	-1	-5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net unrealized gain on available-for-sale securities, net of tax
78	-43	-68	77	75	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other comprehensive (loss) income:
-25	-166	-211	76	70	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-99,357	-99,667	-94,284	-120,353	-86,351	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss per basic and diluted common share:
Basic and diluted net loss per common share
-1.39	-1.81	-1.72	-2.27	-1.63	-1.88	-1.71	-1.94	-1.54	-1.04	-1.24	-3.88	-1.33	-1.83	-1.70	-3.37	-2.17	-3.12	-2.62	-2.10	-1.86	-1.62	-1.17	-1.03	-0.91	-0.92	-0.68	-0.72	-0.60	-0.81	-0.71	-0.61	-0.86	-1.30	-10.73	-14.32	-6.64
Basic and diluted weighted average common shares outstanding
71,662	54,834	54,707	53,028	52,891	52,724	52,669	52,223	50,602	49,973	48,917	45,176	44,039	38,624	38,538	38,389	38,360	38,321	37,613	34,088	34,011	33,941	33,921	33,872	33,820	31,811	30,047	26,717	26,034	25,948	25,906	25,744	22,041	11,498	1,289	1,292	1,254
Product
Cost of sales
9,096	7,942	8,134	6,445	7,405	6,182	4,766	4,490	4,006	3,332	3,026	2,730	1,163	70	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Intangible assets amortization
Cost of sales
1,212	1,211	1,212	1,217	1,120	778	771	709	372	370	372	372	372	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-